SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

ZYNRELEF

HRTX·HERON THERAPEUTICS, INC. /DE/
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercialized (FDA approved May 2021). Under the CorMedix asset purchase agreement, ZYNRELEF will transfer to CorMedix upon deal close, expected Q1 2027.
Why 4/10
ZYNRELEF is already FDA-approved and commercially marketed with no pending PDUFA, pivotal readout, or AdComm in the next 12 months. The next hard catalyst is the closing of the CorMedix asset sale (expected Q1 2027), but M&A is excluded from impact scoring per the rubric. As an approved drug with no pending regulatory binary, the impact score is capped at 3-5.
Actionable Insight NEUTRAL

ZYNRELEF is now part of the asset sale to CorMedix (CRMD), expected to close in Q1 2027. For HRTX shareholders, the stock is transitioning into a stub: Heron will retain CRMD shares, net operating loss carryforwards (~$2.3B), and earn-out rights. The next event is the shareholder vote and regulatory clearance for the sale. For investors tracking ZYNRELEF specifically, watch CorMedix's commercial execution post-close and any label expansion efforts under new ownership.

Price Chart

Loading chart...

Executive Summary

ZYNRELEF (bupivacaine/meloxicam) is an FDA-approved non-opioid extended-release injection for postoperative pain management, developed by Heron Therapeutics (HRTX). First approved in May 2021 with a label expansion in January 2024, it is one of four commercial-stage products Heron is selling to CorMedix Therapeutics (CRMD) in a deal announced November 9, 2026, valued at approximately $223M upfront plus earn-outs. ZYNRELEF revenue grew 13.8% YoY in Q3 2026, but Heron's overall revenue declined 7.8% amid a CINVANTI patent loss and strategic reset. The asset sale is expected to close in Q1 2027, after which CorMedix will commercialize ZYNRELEF alongside its other hospital products.

How It Works

ZYNRELEF is a fixed-dose combination of two drugs in one injection: bupivacaine, a local anesthetic that numbs the area by blocking nerve signals, and meloxicam, a non-steroidal anti-inflammatory drug (NSAID) that reduces inflammation and pain. It is administered as a single dose into the surgical site during a procedure and uses Heron's Biochronomer technology to release the drugs slowly over approximately 72 hours, providing extended pain relief without the need for opioids.

Trial Status

ZYNRELEF is FDA-approved for management of postoperative pain for up to 72 hours in adults. The indication was expanded in January 2024 to include additional orthopedic and soft tissue procedures. It also received European Commission authorization in September 2020.

The Two-Sided Case

▲ Bull Case5
ZYNRELEF is an FDA-approved, differentiated non-opioid for postoperative pain, combining a local anesthetic (bupivacaine) with an NSAID (meloxicam) in an extended-release formulation that provides up to 72 hours of pain relief.
ZYNRELEF net revenue grew 13.8% YoY in Q3 2026, showing continued commercial uptake despite a challenging competitive landscape.
The non-opioid pain management market is expanding: new state laws require insurers to cover non-opioid pain meds, and the FDA approved Journavx (suzetrigine) in 2026, the first new pain-drug class in decades, raising awareness for the category.
CorMedix (CRMD) is acquiring ZYNRELEF along with three other hospital products, expecting the deal to be immediately accretive and targeting $45-60M in annual cost synergies by end of 2027, which could improve the drug's profitability.
ZYNRELEF was included in CMS's proposed 2025 Non-Opioid Policy for Pain Relief under OPPS, which could drive favorable reimbursement and utilization in hospital outpatient settings.
▼ Bear Case5
ZYNRELEF faces entrenched competition from Pacira's Exparel (bupivacaine liposome), which has a longer market history and is now being acquired by Viatris (VTRS) for $1.65B, creating a well-capitalized rival.
Heron's total Q3 2026 revenue fell 7.8% YoY to $35.3M, missing consensus of $37.5M, suggesting the Acute Care franchise is not gaining traction fast enough.
Analyst sentiment has soured: HC Wainwright downgraded to Neutral and Needham downgraded to Hold in mid-2026, with the consensus now 0 Buy, 4 Hold, 1 Sell, 2 Strong Sell.
The asset sale to CorMedix at ~$223M upfront values Heron's entire portfolio (four products) at a fraction of prior analyst price targets, implying limited standalone value for ZYNRELEF.
The CINVANTI patent loss in Delaware District Court (June 2026) forced Heron to reset its strategy and seek a sale, indicating intellectual property risk across the portfolio.

Upcoming Catalysts

  • Closing of CorMedix asset acquisition (expected Q1 2027) - shareholder vote and regulatory clearances
  • CorMedix integration and commercial execution for ZYNRELEF post-close
  • Potential label expansion or new clinical data under CorMedix ownership

Source Filing

The SecBot filing or press-release report that triggered this drug report:

HERON THERAPEUTICS, INC. /DE/ DEFA14A HRTX ·Originating report

Sources · 9

Hover a chip for the title
1 markets.businessinsider.com2 markets.businessinsider.com3 nasdaq.com4 prnewswire.com5 rttnews.com6 msn.com7 krqe.com8 morningstar.com9 globenewswire.com